Global /United States /Healthcare /Diagnostics & Research /RVTY
chevron_leftBack

Revvity, Inc.

RVTY
NYSE: RVTY Delayed
93.82USD 1.6%
As of 24 April 2025, Revvity, Inc. has a market cap of $11.27B USD, ranking #1546 globally and #569 in the United States. It ranks #135 in the Healthcare sector, and #17 in the Diagnostics & Research industry.
Global Rank
1546
Country Rank
569
Sector Rank
135
Industry Rank
17
Key Stats
Market Cap
$11.27BUSD
Enterprise Value
$13.44BUSD
Revenue (TTM)
$2.76BUSD
EBITDA (TTM)
$837.64MUSD
Net Income (TTM)
$270.39MUSD
EBITDA Margin
30%
Profit Margin
9.8%
PE Ratio
42.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Prahlad Singh open_in_new
Employees
11,000
Founded
1937
Website
revvity.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.6% 0.1% -13% -24% -21% -6.9%
Upcoming Earnings
Earnings Date
Mon, Apr 28
Earnings Time
sunny Before Open
EPS Estimate
$0.9600 -2% yoy
Revenue Estimate
$662.3M 1.9% yoy

Markets

Exchange Ticker Price
NYSE
MIC: XNYS
PRIMARY
RVTY
Revvity Inc
ISIN: US7140461093
Shares Out.:
120.147M1 Shares Float: 119.643M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
93.82 USD
London Stock Exchange
MIC: XLON
0KHE
Revvity Inc
ISIN: US7140461093
TV:
SA:
YF:
GF:
BA:
MS:
92.75 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Revvity, Inc.

Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Similar Companies

Industry: Diagnostics & Research (United States)
Name
Market Cap diff.
Thermo Fisher Scientific Inc.
TMO
$162.94B
1K%
Danaher Corp.
DHR
$140.45B
1K%
IDEXX Laboratories, Inc.
IDXX
$34.63B
207%
Agilent Technologies, Inc.
A
$29.94B
166%
IQVIA Holdings Inc.
IQV
$25.93B
130%
Industry: Diagnostics & Research (Global)
Name
Market Cap diff.
Lonza Group AG
LONN
$46.75B
38.79B CHF
315%
WuXi AppTec Co., Ltd.
603259
$22.16B
161.5B CNY
97%
bioMérieux S.A.
BIM
$15.1B
13.33B EUR
34%
ICON Public Limited Co.
ICLR
$11.56B
2.5%
Eurofins Scientific SE
ERF
$11.41B
10.07B EUR
1.2%